The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Chronic Obstructive Pulmonary Disease Drugs-Global Market Insights and Sales Trends 2024

Chronic Obstructive Pulmonary Disease Drugs-Global Market Insights and Sales Trends 2024

Publishing Date : Nov, 2023

License Type :
 

Report Code : 1836671

No of Pages : 104

Ask Your Query
Synopsis
Chronic obstructive pulmonary disease ( COPD ) is a chronic inflammatory lung disease that causes obstructed airflow from the lungs.
The global Chronic Obstructive Pulmonary Disease Drugs market size is expected to reach US$ 32360 million by 2029, growing at a CAGR of 5.0% from 2023 to 2029. The market is mainly driven by the significant applications of Chronic Obstructive Pulmonary Disease Drugs in various end use industries. The expanding demands from the Emphysema, Chronic Bronchitis, Refractory Asthma and Others, are propelling Chronic Obstructive Pulmonary Disease Drugs market. Inhalers, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Nebulizers segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Chronic Obstructive Pulmonary Disease Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Chronic Obstructive Pulmonary Disease Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Chronic Obstructive Pulmonary Disease Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Chronic Obstructive Pulmonary Disease Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Chronic Obstructive Pulmonary Disease Drugs covered in this report include AstraZeneca, Boehringer Ingelheim, GSK, Novartis, Teva Pharmaceuticals, Ache Laboratorios Farmaceuticos, Almirall, Aquinox Pharmaceuticals and Ario Pharma, etc.
The global Chronic Obstructive Pulmonary Disease Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AstraZeneca
Boehringer Ingelheim
GSK
Novartis
Teva Pharmaceuticals
Ache Laboratorios Farmaceuticos
Almirall
Aquinox Pharmaceuticals
Ario Pharma
Asmacure
Astellas Pharma
BioMarck Pharmaceuticals
Global Chronic Obstructive Pulmonary Disease Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Chronic Obstructive Pulmonary Disease Drugs market, Segment by Type:
Inhalers
Nebulizers
Global Chronic Obstructive Pulmonary Disease Drugs market, by Application
Emphysema
Chronic Bronchitis
Refractory Asthma
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Chronic Obstructive Pulmonary Disease Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Chronic Obstructive Pulmonary Disease Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index
1 Chronic Obstructive Pulmonary Disease Drugs Market Overview
1.1 Chronic Obstructive Pulmonary Disease Drugs Product Overview
1.2 Chronic Obstructive Pulmonary Disease Drugs Market Segment by Type
1.2.1 Inhalers
1.2.2 Nebulizers
1.3 Global Chronic Obstructive Pulmonary Disease Drugs Market Size by Type
1.3.1 Global Chronic Obstructive Pulmonary Disease Drugs Market Size Overview by Type (2018-2029)
1.3.2 Global Chronic Obstructive Pulmonary Disease Drugs Historic Market Size Review by Type (2018-2023)
1.3.3 Global Chronic Obstructive Pulmonary Disease Drugs Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Chronic Obstructive Pulmonary Disease Drugs Sales Breakdown by Type (2018-2023)
1.4.2 Europe Chronic Obstructive Pulmonary Disease Drugs Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Chronic Obstructive Pulmonary Disease Drugs Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Chronic Obstructive Pulmonary Disease Drugs Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Sales Breakdown by Type (2018-2023)
2 Global Chronic Obstructive Pulmonary Disease Drugs Market Competition by Company
2.1 Global Top Players by Chronic Obstructive Pulmonary Disease Drugs Sales (2018-2023)
2.2 Global Top Players by Chronic Obstructive Pulmonary Disease Drugs Revenue (2018-2023)
2.3 Global Top Players by Chronic Obstructive Pulmonary Disease Drugs Price (2018-2023)
2.4 Global Top Manufacturers Chronic Obstructive Pulmonary Disease Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Chronic Obstructive Pulmonary Disease Drugs Market Competitive Situation and Trends
2.5.1 Chronic Obstructive Pulmonary Disease Drugs Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Chronic Obstructive Pulmonary Disease Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Chronic Obstructive Pulmonary Disease Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into Chronic Obstructive Pulmonary Disease Drugs Market
2.8 Key Manufacturers Chronic Obstructive Pulmonary Disease Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Chronic Obstructive Pulmonary Disease Drugs Status and Outlook by Region
3.1 Global Chronic Obstructive Pulmonary Disease Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Chronic Obstructive Pulmonary Disease Drugs Historic Market Size by Region
3.2.1 Global Chronic Obstructive Pulmonary Disease Drugs Sales in Volume by Region (2018-2023)
3.2.2 Global Chronic Obstructive Pulmonary Disease Drugs Sales in Value by Region (2018-2023)
3.2.3 Global Chronic Obstructive Pulmonary Disease Drugs Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Chronic Obstructive Pulmonary Disease Drugs Forecasted Market Size by Region
3.3.1 Global Chronic Obstructive Pulmonary Disease Drugs Sales in Volume by Region (2024-2029)
3.3.2 Global Chronic Obstructive Pulmonary Disease Drugs Sales in Value by Region (2024-2029)
3.3.3 Global Chronic Obstructive Pulmonary Disease Drugs Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Chronic Obstructive Pulmonary Disease Drugs by Application
4.1 Chronic Obstructive Pulmonary Disease Drugs Market Segment by Application
4.1.1 Emphysema
4.1.2 Chronic Bronchitis
4.1.3 Refractory Asthma
4.1.4 Others
4.2 Global Chronic Obstructive Pulmonary Disease Drugs Market Size by Application
4.2.1 Global Chronic Obstructive Pulmonary Disease Drugs Market Size Overview by Application (2018-2029)
4.2.2 Global Chronic Obstructive Pulmonary Disease Drugs Historic Market Size Review by Application (2018-2023)
4.2.3 Global Chronic Obstructive Pulmonary Disease Drugs Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Chronic Obstructive Pulmonary Disease Drugs Sales Breakdown by Application (2018-2023)
4.3.2 Europe Chronic Obstructive Pulmonary Disease Drugs Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Chronic Obstructive Pulmonary Disease Drugs Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Chronic Obstructive Pulmonary Disease Drugs Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Sales Breakdown by Application (2018-2023)
5 North America Chronic Obstructive Pulmonary Disease Drugs by Country
5.1 North America Chronic Obstructive Pulmonary Disease Drugs Historic Market Size by Country
5.1.1 North America Chronic Obstructive Pulmonary Disease Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Chronic Obstructive Pulmonary Disease Drugs Sales in Volume by Country (2018-2023)
5.1.3 North America Chronic Obstructive Pulmonary Disease Drugs Sales in Value by Country (2018-2023)
5.2 North America Chronic Obstructive Pulmonary Disease Drugs Forecasted Market Size by Country
5.2.1 North America Chronic Obstructive Pulmonary Disease Drugs Sales in Volume by Country (2024-2029)
5.2.2 North America Chronic Obstructive Pulmonary Disease Drugs Sales in Value by Country (2024-2029)
6 Europe Chronic Obstructive Pulmonary Disease Drugs by Country
6.1 Europe Chronic Obstructive Pulmonary Disease Drugs Historic Market Size by Country
6.1.1 Europe Chronic Obstructive Pulmonary Disease Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Chronic Obstructive Pulmonary Disease Drugs Sales in Volume by Country (2018-2023)
6.1.3 Europe Chronic Obstructive Pulmonary Disease Drugs Sales in Value by Country (2018-2023)
6.2 Europe Chronic Obstructive Pulmonary Disease Drugs Forecasted Market Size by Country
6.2.1 Europe Chronic Obstructive Pulmonary Disease Drugs Sales in Volume by Country (2024-2029)
6.2.2 Europe Chronic Obstructive Pulmonary Disease Drugs Sales in Value by Country (2024-2029)
7 Asia-Pacific Chronic Obstructive Pulmonary Disease Drugs by Region
7.1 Asia-Pacific Chronic Obstructive Pulmonary Disease Drugs Historic Market Size by Region
7.1.1 Asia-Pacific Chronic Obstructive Pulmonary Disease Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Chronic Obstructive Pulmonary Disease Drugs Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Chronic Obstructive Pulmonary Disease Drugs Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Chronic Obstructive Pulmonary Disease Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific Chronic Obstructive Pulmonary Disease Drugs Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Chronic Obstructive Pulmonary Disease Drugs Sales in Value by Region (2024-2029)
8 Latin America Chronic Obstructive Pulmonary Disease Drugs by Country
8.1 Latin America Chronic Obstructive Pulmonary Disease Drugs Historic Market Size by Country
8.1.1 Latin America Chronic Obstructive Pulmonary Disease Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Chronic Obstructive Pulmonary Disease Drugs Sales in Volume by Country (2018-2023)
8.1.3 Latin America Chronic Obstructive Pulmonary Disease Drugs Sales in Value by Country (2018-2023)
8.2 Latin America Chronic Obstructive Pulmonary Disease Drugs Forecasted Market Size by Country
8.2.1 Latin America Chronic Obstructive Pulmonary Disease Drugs Sales in Volume by Country (2024-2029)
8.2.2 Latin America Chronic Obstructive Pulmonary Disease Drugs Sales in Value by Country (2024-2029)
9 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs by Country
9.1 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Historic Market Size by Country
9.1.1 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 AstraZeneca
10.1.1 AstraZeneca Company Information
10.1.2 AstraZeneca Introduction and Business Overview
10.1.3 AstraZeneca Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue and Gross Margin (2018-2023)
10.1.4 AstraZeneca Chronic Obstructive Pulmonary Disease Drugs Products Offered
10.1.5 AstraZeneca Recent Development
10.2 Boehringer Ingelheim
10.2.1 Boehringer Ingelheim Company Information
10.2.2 Boehringer Ingelheim Introduction and Business Overview
10.2.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Drugs Products Offered
10.2.5 Boehringer Ingelheim Recent Development
10.3 GSK
10.3.1 GSK Company Information
10.3.2 GSK Introduction and Business Overview
10.3.3 GSK Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue and Gross Margin (2018-2023)
10.3.4 GSK Chronic Obstructive Pulmonary Disease Drugs Products Offered
10.3.5 GSK Recent Development
10.4 Novartis
10.4.1 Novartis Company Information
10.4.2 Novartis Introduction and Business Overview
10.4.3 Novartis Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Novartis Chronic Obstructive Pulmonary Disease Drugs Products Offered
10.4.5 Novartis Recent Development
10.5 Teva Pharmaceuticals
10.5.1 Teva Pharmaceuticals Company Information
10.5.2 Teva Pharmaceuticals Introduction and Business Overview
10.5.3 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Products Offered
10.5.5 Teva Pharmaceuticals Recent Development
10.6 Ache Laboratorios Farmaceuticos
10.6.1 Ache Laboratorios Farmaceuticos Company Information
10.6.2 Ache Laboratorios Farmaceuticos Introduction and Business Overview
10.6.3 Ache Laboratorios Farmaceuticos Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Ache Laboratorios Farmaceuticos Chronic Obstructive Pulmonary Disease Drugs Products Offered
10.6.5 Ache Laboratorios Farmaceuticos Recent Development
10.7 Almirall
10.7.1 Almirall Company Information
10.7.2 Almirall Introduction and Business Overview
10.7.3 Almirall Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Almirall Chronic Obstructive Pulmonary Disease Drugs Products Offered
10.7.5 Almirall Recent Development
10.8 Aquinox Pharmaceuticals
10.8.1 Aquinox Pharmaceuticals Company Information
10.8.2 Aquinox Pharmaceuticals Introduction and Business Overview
10.8.3 Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Products Offered
10.8.5 Aquinox Pharmaceuticals Recent Development
10.9 Ario Pharma
10.9.1 Ario Pharma Company Information
10.9.2 Ario Pharma Introduction and Business Overview
10.9.3 Ario Pharma Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Ario Pharma Chronic Obstructive Pulmonary Disease Drugs Products Offered
10.9.5 Ario Pharma Recent Development
10.10 Asmacure
10.10.1 Asmacure Company Information
10.10.2 Asmacure Introduction and Business Overview
10.10.3 Asmacure Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Asmacure Chronic Obstructive Pulmonary Disease Drugs Products Offered
10.10.5 Asmacure Recent Development
10.11 Astellas Pharma
10.11.1 Astellas Pharma Company Information
10.11.2 Astellas Pharma Introduction and Business Overview
10.11.3 Astellas Pharma Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Astellas Pharma Chronic Obstructive Pulmonary Disease Drugs Products Offered
10.11.5 Astellas Pharma Recent Development
10.12 BioMarck Pharmaceuticals
10.12.1 BioMarck Pharmaceuticals Company Information
10.12.2 BioMarck Pharmaceuticals Introduction and Business Overview
10.12.3 BioMarck Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue and Gross Margin (2018-2023)
10.12.4 BioMarck Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Products Offered
10.12.5 BioMarck Pharmaceuticals Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Chronic Obstructive Pulmonary Disease Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Chronic Obstructive Pulmonary Disease Drugs Industrial Chain Analysis
11.4 Chronic Obstructive Pulmonary Disease Drugs Market Dynamics
11.4.1 Chronic Obstructive Pulmonary Disease Drugs Industry Trends
11.4.2 Chronic Obstructive Pulmonary Disease Drugs Market Drivers
11.4.3 Chronic Obstructive Pulmonary Disease Drugs Market Challenges
11.4.4 Chronic Obstructive Pulmonary Disease Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Chronic Obstructive Pulmonary Disease Drugs Distributors
12.3 Chronic Obstructive Pulmonary Disease Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock